B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab

E Wiesik-Szewczyk
M Olesinska
Institute of Rheumatology, Department of Connective Tissue Diseases, Warsaw, Poland

Abstract: Systemic lupus erythematosus (SLE) is a complex autoimmune disease of unknown etiology, and the limited available therapeutic options for this disease, are frustrating to both clinicians and patients. However, recent advances in the understanding of disease mechanisms have given rise to numerous studies on specific approaches to SLE treatment. Rituximab, the first chimeric, mouse-human monoclonal antibody which is directed against CD20, seems to be a new therapeutic option. The purpose of this review is to explain the current clinical evidence on the therapeutic use of rituximab in adult SLE patients. Two randomized clinical trials with rituximab (the EXPLORER and LUNAR studies) failed to prove efficacy of this drug on SLE. Ongoing data analysis continues to explain the reasons behind why this treatment fails to work. However data from open source and observational studies contrast with clinical trials results. The global analysis of this data supports the off-label use of rituximab in subsets of SLE that are refractory to standard treatment.

Keywords: B cells, systemic lupus erythematosus, rituximab, off-label use, clinical trials

SLE, overview of the diseases
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a heterogeneous clinical picture and an unpredictable prognosis. Clinical symptoms include arthralgia, arthritis, skin rashes, serositis, hematological abnormalities, and can lead to severe central nervous system dysfunction and renal inflammation, which can ultimately result in renal insufficiency that requires dialysis. The clinical symptoms are accompanied with immunologic abnormalities that include the presence of antinuclear antibodies, antibodies that are specific to double-stranded deoxyribonucleic acid, and the Smith antigen. Complement activation including the presence of circulating complement split products and depressed levels of C3 and C4 complement in the serum accompany serological abnormalities.

Due to protean clinical presentation and the lack of a unique confirmatory test, diagnosis of SLE remains a challenge. To identify patients in clinical studies, the American College of Rheumatology criteria for the classification of SLE are used (Table 1). A person has SLE if at least 4 of the 11 criteria are present either simultaneously or serially during an observation period. Criteria 1–9 are clinical, while 10 and 11 pertain to a positive serological test. Patients included in Phase III clinical trials have had to fulfill at least one of the immunological criteria.

Standard of care therapy for SLE typically involves antimalarials, combined with corticosteroids and non-steroidal anti-inflammatory drugs. In more...
The revised criteria for the classification of systemic lupus erythematosus

**Criteria for the classification of systemic lupus erythematosus**

**Clinical criteria**
1. Malar rash
2. Discoid rash
3. Photosensitivity
4. Oral ulcers
5. Arthritis
6. Serositis
7. Renal disorder
8. Neurological disorder
9. Hematological disorder

**Immunological criteria**
10. Anti-DNA
11. Anti-Sm
12. Anti-phospholipids
13. Lupus anticoagulant
14. False positive serological test for syphilis
15. Abnormal titer of ANA

**Abbreviations:** DNA, deoxyribonucleic acid; Sm, Smith antigen; ANA, antinuclear antibodies.

Severe cases, when there is more internal organ involvement or corticosteroid-dependence, non-selective immunomodulatory and immunosuppressive agents are used, such as azathioprine, methotrexate, mycophenolate mofetil (MMF), cyclophosphamide, and cyclosporine. For severe, refractory, or recurrent diseases, combinations of therapies might be mandatory.

Current therapies are often ineffective in sustaining remission of the disease. They may also have to be administered over a prolonged time period and in doses associated with substantial adverse events and drug-related complications. In long-term follow-up, the majority of patients suffer from organ damage. Still, mortality rates among SLE patients are higher than among healthy populations. The increased mortality rate is largely a function of the lupus itself, resultant infections, and in later stages can be associated with cardiovascular complications. This bimodal pattern of lupus mortality rates was recognized 30 years ago and remains unchanged. Therefore, treatments that involve lower doses of corticosteroids, or therapies that are more effective and better tolerated than cytotoxic drugs are needed.

In the past decade, biologics targeting immune cells, costimulatory pathways, and selected cytokines, or their receptors have been approved for the treatment of a wide variety of autoimmune diseases. Surprisingly, the results of clinical trials have been disappointing for SLE, a set of prototypic B-cell dependent diseases. The exception to this has been belimumab, a B-cell activating factor inhibitor, which was the first new drug in 50 years to be approved for SLE treatment; however, the clinical efficacy of belimumab seems to be modest.

The other B-cell targeted agent, rituximab, failed to meet primary end-points in two clinical trials, but is widely used in an off-label manner. This review will focus on the potential of rituximab in the treatment of SLE patients in clinical practice.

**SLE and B lymphocytes**

B cells play a crucial pathologic role in SLE. Abnormal B cell proliferation, maturation, prolonged life-span of auto reactive clones, and autoantibody production are documented along with immune deregulation and tolerance breakdown. Some SLE patients have abnormal selection at the immature to early transitional stage due to intrinsic B cell defects. Auto reactive B cells in SLE differentiate into memory and plasma cells. In immature bone marrow, diminished auto reactive B cell deletion is associated with polymorphisms in gene encoding modulators of BCR signaling, such as PTPN22 and BLK. In antigen activated mature B cells, differentiation to effector cells is stimulated by T cell help and costimulation, enhanced BCR signals via CD19 upregulation, increased TLR signals, or impaired negative signals mediated trough FcγRIIB and CD22. Abnormal B cell function is characterized by the production of autoantibodies – a serologic hallmark of SLE. Another abnormal B cell function is cytokine secretion. B cells have been shown to produce interleukin-4, 6, 10, interferon gamma, transforming growth factor beta, and lymphotoxin alfa. The overproduction of cytokines in SLE can lead to amplification of autoimmune response. B cells are also antigen presenting cells; B cells activate T cells by surface expression of peptide-MHC complex that interact with T cell receptors.

In summary B cells play a crucial role in SLE pathogenesis through the presentation of self-antigens, T cell activation, and through the production of autoantibodies and cytokines. All of the above have provided the rationale for the use of B cell directed therapy in SLE treatment.

Rituximab is the first chimeric, mouse-human monoclonal antibody which is directed against CD20. CD20 is a B lymphocyte restricted surface molecule that is expressed from pre-B to memory B cells. Despite intensive studies, the precise function of rituximab remains puzzling. CD20-knockout mice do not present with specific phenotype abnormalities and seem to preserve...
normal immunologic response, and in addition, CD20 has no known natural ligand. It is a phosphoprotein with a structure of four transmembrane regions and an amino-acid extracellular loop. According to structural homologies, it is supposed that CD20 may have a calcium channel function. Administration of the CD20-specific antibody results in the death of B cells, which is achieved by antibody-dependent cell-mediated cytotoxicity, complement-mediated lyses, or apoptosis.

Rituximab does not target pre-B cells, plasmablasts, or plasma cells producing disease-specific autoantibodies (double-stranded deoxyribonucleic acid or anti-Smith antigens), which can lead to diminished efficacy of the drug in patients with B cell depletion who demonstrate poor serologic response. On the other hand, the decline of autoantibodies is not always associated with a good clinical response. It seems reasonable that different symptoms of SLE result from different mechanisms and are not always autoantibody-dependent.

Rituximab influences homeostasis and improves the disturbances found in peripheral B cells that are characteristic of active SLE, and it affects both the cellular and the humoral arm of the immune system. After effective B cell depletion during a reconstitution period, naive B cell lymphopenia, expansion of a CD27-, IgD- (double negative) population, and expansion of circulating plasmablasts are significantly decreased. In addition, the frequency of auto reactive memory B cells was found to be decreased 1 year post-treatment. However, the magnitude, duration, and consequences of depletion therapy in SLE have not yet been completely elucidated. Long-term follow-up (mean duration 41 months) has shown a delayed recovery of memory CD27+ B cells in peripheral blood and lymphoid tissue after rituximab administration.

B cell levels after rituximab administration have been measured in clinical trials, but their importance in clinical practice has not been proven. The grade of B cell depletion by routine measures was not predictive for a clinical response. It was suggested that the timing of retreatment for patients with rheumatoid arthritis and vasculitis should be based mainly on clinical activity. However, measurement by highly sensitive flow cytometry, which can define B cell numbers 50–100 times lower than conventional techniques, predicts the overall effectiveness of rituximab. In a recent study of 39 patients with active SLE treated with rituximab, clinical outcomes correlated with the level of B cell depletion. Moreover, plasmablast repopulation was significantly faster in patients with earlier relapse when compared to patients with later relapse. In clinical practice, the regimen and tools for B cell depletion assessment in SLE patients have yet to be determined.

**Clinical trials**

**EXPLORER STUDY – Rituximab in moderately to severely active extra-renal SLE**

The aim of a placebo-controlled, double-blind, multicenter study was to assess the efficacy and safety of rituximab in patients with moderately or severely active extra-renal SLE.

All subjects included into the study had to fulfill the American College of Rheumatology classification criteria, including a positive test for antinuclear antibodies. Activity of the disease was defined using the British Isles Lupus Assessment Group (BILAG) organ system, which scores patients based on the need for alterations and intensification of therapy. Severe disease was indicated if more than one organ system was scored as A, and a moderate form of the disease was indicated if at least two organ systems received a B score. Patients received a stable dose of one immunosuppressive drug at entry, which was maintained during the trial.

Exclusion criteria involved patients with severe central nervous system or organ-threatening lupus, or any conditions requiring significant use of steroids, or recent treatment with cyclophosphamide or calcineurin inhibitors.

Patients were randomized at a 2:1 ratio to receive either rituximab or placebo on days 1, 15, 168, and 182, and these were added to their current standard of care therapy: the baseline immunosuppressive regimen (azathioprine, mycophenolat mofetil, or methotrexate) and prednisone, given according to the protocol (daily dose at least 0.5 mg/kg) to achieve immediate control of symptoms.

Primary endpoints were clinical response defined as achieving BILAG C scores or better in all organs at week 24 without experiencing a severe flare from day 1 to week 24, and maintaining this response to week 52. Treatment failure was noted upon one new BILAG B score after 6 months, which is very rigorous.

The trial enrolled 257 patients with significant disease activity (81% entered with 1 ≥ BILAG A score or 3 ≥ BILAG B score), mostly in mucocutaneous or musculoskeletal systems, and with constitutional features. It should be noted that safety, tolerability, and the patient dropout rate was similar across both patients receiving placebo and those receiving rituximab.
No differences were observed between placebo and rituximab in the efficacy end-points. In both groups, significant improvement was observed by day 28 due to initial steroid treatment and was maintained after dose tapering. However in the African American/Hispanic group, which comprised one-third of patients, the clinical response differed significantly between the placebo and treatment arms (P = 0.0408), which suggested the beneficial effect of rituximab in this subgroup.

Further evaluation of patient subsets and biomarkers has since continued. Recently, exploratory reanalysis of data from the EXPLORER study was conducted, considering alternative definitions for flare. The paper analyzed patients who achieved low disease activity (BILAG C or D) at any point prior to week 52. The following variables were assessed: time to first severe flare (≥1 A BILAG score or ≥3 B BILAG scores), time to first A BILAG flare, and the number of A flares per patient per year. No difference was observed between those taking rituximab and placebo in preventing or delaying flares when accounting for both severe and moderate flares. However, those in the rituximab group demonstrated a longer time to the first A flare as well as a significant decrease of A flares per patient per year compared with those in the placebo group. In summary, the authors stated that no conclusion about rituximab efficacy can be drawn. The data suggest that rituximab may lessen severe flares defined by BILAG A score. Moreover, the data confirm the necessity for the revision in design of future clinical studies. The analyses based on BILAG A flares may be more specific and clinically significant.

Another possibility is use of compound variables to assess patient outcomes, as performed in the Phase III studies of belimumab. The new robust Systemic Lupus Erythematosus Responder Index assesses improvements in disease activity without worsening the overall condition or the development of significant diseases activity in new organ systems. The Responder Index is defined as (1) a ≥4-point reduction in the SELENA-SLEDAI score; (2) no new BILAG A, or no more than one new BILAG B domain score; and (3) no deterioration from baseline in the physician’s global assessment by ≥0.3 points.

The EXPLORER trial accomplished some important tasks including enrolling demonstrably ill patients, setting strict background rules for therapy, providing clear definitions of efficacy endpoints, and identifying treatment failure cut-off sensitivity points. Negative results suggest that the disease is more biologically heterogeneous and is not uniquely B-cell driven. Moreover the methods used to rate clinical activity were probably not optimal. The trial also did not examine the possibility of synergic use of cyclophosphamide, which was one of exclusion criteria.

LUNAR STUDY – rituximab in active proliferative lupus nephritis

The aim of this study was to assess whether the addition of rituximab to a background of MMF plus corticosteroids is beneficial in patients with proliferative lupus nephritis. Patients were eligible if they were diagnosed with SLE according to the American College of Rheumatology criteria and had a history of positive antinuclear antibodies. Patients required a diagnosis of lupus nephritis (LN) that was supported by both renal biopsy and proteinuria (presenting with a urine/protein/creatinine ratio > 1). If the biopsy was performed > 3 months before screening, the collection of active urinary sediment was also required.

Patients were randomized 1:1 to receive either placebo or rituximab. MMF was initiated at 1.5 g/day and increased to 3 g/day by week 4, and maintained through the study. Methylprednisolone 1000 mg was administered intravenously prior to administration of the study drug on day 1, and across the consecutive 3 days as therapy for active LN. Subsequently, oral prednisone was given (0.75 mg/kg/day) until day 16, and tapered to ≤10 mg/day by week 16. Other immunosuppressive agents were not allowed. Any new immunosuppressants or the introduction of high dose corticoids required that participants discontinued their participation in the study, and subjects were identified as experiencing treatment failure.

The primary efficacy endpoint was renal response, defined as complete renal response (CRR), partial renal response (PRR), or no response at week 52 (Table 2). Secondary end-points were CRRs sustained from week 24 through 52, CRR rates at week 52, reduction in baseline urine/protein/creatinine (UPC) from >3.0 to <1.0 at week 52 and time to first CRR.

The trial enrolled 144 patients. Sixty nine percent of the patients were first diagnosed with LN within 2 years of randomization, and half experienced their first episode of LN. Renal response rate (CRR, partial renal response, or no response) at week 52 was not statistically different between the rituximab and the placebo group. (P = 0.55). Again, as in the EXPLORER trial, a prespecified subgroup analysis of the overall renal response revealed that at week 52, black patients treated with rituximab had a higher response rate than the placebo group (70% vs 45%). Regarding secondary endpoints, rituximab exhibited a reduction of UPC at week 52, and the difference between the two groups was statistically significant at week 78 (P < 0.04). Similarly, the rituximab
group was more likely to achieve CRR with respect to proteinuria at week 78 ($P = 0.04$). There were no statistically significant differences in other secondary endpoints.

LUNAR is the largest randomized placebo controlled study to evaluate the effect of rituximab added to initial therapy for active proliferative LN. The study outcomes did not meet primary efficacy endpoints, although there were more PRR in the rituximab group. These data are in disagreement with previous uncontrolled studies of LN that had shown favorable responses to rituximab. However, it is important to note that these open studies enrolled patients who were mainly refractory to therapies with cyclophosphamide or MMF; LUNAR excluded such patients. Moreover, half of these patients had their first episode of LN in the LUNAR trial.

### Off-label clinical experience

Uncontrolled clinical studies with rituximab have shown promising results regardless of medication regimens, tools used for assessment, and indications (overall SLE activity, SLE with hemolytic anemia, refractory SLE, lupus nephritis, or severe central nervous system involvement). Results of published clinical studies that enrolled at least 10 patients are listed in Table 3. A systematic review of off-label rituximab use in refractory SLE documented a significant improvement in at least one organ manifestation in majority of patients (90%). The French Autoimmunity and Rituximab Registry presented data patients treated with rituximab in regular clinical practice. Overall response was defined by SELENA-SLEDAI reduction ≥ 3. An organ-system response was defined as a 50% improvement (partial response) or disappearance of baseline manifestations (complete response). The study involved 136 patients with mild to severe SLE (the mean SELENA-SLEDAI = 11.3). A total of 42 patients had LN. Rituximab was added to a stable background immunosuppressive therapy (59 patients) or given in combination with new immunosuppressive agents (12 patients). The mean duration of follow-up was 18 months.

SELENA-SLEDAI reduction was observed in 80 of 113 patients available for analysis (71%). The most significant improvement was observed in articular, cutaneous, renal, and hematological symptoms, and patients achieved at least a 70% improvement in their symptoms (combined partial and complete response). Moreover, a statistically significant steroid-sparing effect was observed. Among the responders, 41% experienced a flare and of those, 90% subsequently responded to rituximab re-treatment. The authors concluded that analysis of data from the French registry showed that the efficacy of rituximab in SLE patients was significant in actual clinical practice.

Recently pooled data from European cohorts diagnosed with biopsy-proven LN were published. Analysis involved 164 patients. In 82 (50%) cases, rituximab was administered to patients with LN that was refractory to standard therapies; in 69 (42%) cases, rituximab was provided for LN flare; and in 13 (8%) cases, the drug was provided as first line therapy. Rituximab was administered in combination with steroids, cyclophosphamide ($n = 58$), or MMF ($n = 55$). Significant improvements in proteinuria and a reduction in the protein/creatinine ratio were observed at 12 months ($P < 0.001$). Nephrotic syndrome and renal insufficiency at baseline predicted a worse response. The authors concluded that rituximab can be an effective option for patients with LN, especially for those refractory to standard treatment or for those with recurrent flares.

These encouraging results contrast with the poor outcomes reported from both clinical trials. These contradictory findings can be attributed to several reasons including patient selection. The open studies enrolled different populations treated with cyclophosphamide (those with refractory diseases or those with severe CNS). The next issue was the method used to assess clinical activity. The BILAG score is a transitional index developed for intention-to-treat analysis, and might not be perfect for use in regular clinical practice. There are many published analyses suggesting that

Table 2 Criteria for renal response in the LUNAR study

<table>
<thead>
<tr>
<th>Renal response</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete renal response (CRR)</td>
<td>Normal serum creatinine if abnormal at study entry; or Serum creatinine $\leq 115%$ if normal at study entry; and Inactive urinary sediment ($&lt; 5$ RBC/HPF and absence of RBC cast); and Urine/creatinine/protein ratio $&lt; 0.5$</td>
</tr>
<tr>
<td>Partial renal response (PRR)</td>
<td>Serum creatinine $\leq 115%$ if normal at study entry; RBC/HPF $\leq 50%$ above baseline and absence of RBC cast; At least $50%$ decrease in UPC to $&lt; 1.0$ if baseline UPC was $\leq 3.0$; or To $\leq 3.0$ if baseline UPC was above 3.0</td>
</tr>
<tr>
<td>No response</td>
<td>Criteria for CRR or PRR not met; or Early termination; or Inability to assesses endpoint due to missing data; or Initiation of new immunosuppressant; or Corticosteroid rescue therapy</td>
</tr>
</tbody>
</table>

Abbreviations: LUNAR, Lupus Nephritis Assessment with Rituximab; RBC/HPF, red blood cells per high power field; RBC, red blood cells; UPC, urine/protein/creatinine ratio; CRR, complete renal response; PRR, partial renal response.
Table 3 Open-label studies of rituximab in adult patients (n ≥ 10) with systemic lupus erythematosus

<table>
<thead>
<tr>
<th>Author</th>
<th>N of patients</th>
<th>Result</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moderate to severe SLE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Galarza-Maldonado et al</td>
<td>26</td>
<td>Effective</td>
<td>Latin-American Patients, Rituximab followed by hydroxychloroquine and MMF, 50% remission in 24 month</td>
</tr>
<tr>
<td>Catapano et al</td>
<td>31</td>
<td>Effective</td>
<td>RAS remission (partial or complete); 30 months follow-up, Relapses responded for re-treatment</td>
</tr>
<tr>
<td>Leandro et al</td>
<td>24</td>
<td>Effective</td>
<td>Patients refractory to conventional immunosuppressants Global BILAG score improvement</td>
</tr>
<tr>
<td>Looney et al</td>
<td>17</td>
<td>Effective</td>
<td>SLAM score improvement, 12 months follow-up</td>
</tr>
<tr>
<td>Ng et al</td>
<td>32</td>
<td>Effective</td>
<td>Rituximab with cyclophosphamide 36 months follow-up</td>
</tr>
<tr>
<td>Cambridge et al</td>
<td>25</td>
<td>Effective</td>
<td>Negative response correlation with expanded ANA profile and BLyS concentration</td>
</tr>
<tr>
<td>Albert et al</td>
<td>18</td>
<td>Effective</td>
<td>Patients who failed at least one immunosuppressant SLEDAI reduction</td>
</tr>
<tr>
<td>Reynolds et al</td>
<td>11</td>
<td>Effective</td>
<td>BILAG reduction, steroid sparing effect, positive effect for interstitial lung disease</td>
</tr>
<tr>
<td>Tanaka et al</td>
<td>15</td>
<td>Effective</td>
<td>BILAG score reduction</td>
</tr>
<tr>
<td>Lu et al</td>
<td>45</td>
<td>Effective</td>
<td>19 achieved complete remission, 21 achieved partial remission Mexican population</td>
</tr>
<tr>
<td>Garcia-Carrasco et al</td>
<td>52</td>
<td>Effective</td>
<td>Data from French Registry, patient from routine clinical practice Rituximab with cyclophosphamide</td>
</tr>
<tr>
<td>Terrier et al</td>
<td>136</td>
<td>Effective</td>
<td>Severe immune hemolytic anemia</td>
</tr>
<tr>
<td>Jónsdóttir et al</td>
<td>16</td>
<td>Effective</td>
<td>Patients refractory to conventional immunosuppressive treatment</td>
</tr>
<tr>
<td>Gomez-Mennesson et al</td>
<td>26</td>
<td>Effective</td>
<td>Biopsy proven LN, pooled data from European cohort, rituximab in combination with cyclophosphamide or MMF</td>
</tr>
<tr>
<td>Lindholm et al</td>
<td>31</td>
<td>Effective</td>
<td>Potential cost saving in LN Rituximab with MMF in proliferative nephritis</td>
</tr>
<tr>
<td>Lupus nephritis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diaz-Lagares et al</td>
<td>164</td>
<td>Effective</td>
<td>No response in rapidly progressive glomerulonephritis Rituximab with cyclophosphamide</td>
</tr>
<tr>
<td>Lateef et al</td>
<td>10</td>
<td>Effective</td>
<td>Systematic analysis of seven observational studies</td>
</tr>
<tr>
<td>Boletis et al</td>
<td>10</td>
<td>Effective</td>
<td>Significant steroid sparing effect</td>
</tr>
<tr>
<td>Melander et al</td>
<td>20</td>
<td>Effective</td>
<td>Biopsy proven LN, pooled data from European cohort, rituximab in combination with cyclophosphamide or MMF</td>
</tr>
<tr>
<td>Jónsdóttir et al</td>
<td>28</td>
<td>Effective</td>
<td>Biopsy proven LN, pooled data from European cohort, rituximab in combination with cyclophosphamide or MMF</td>
</tr>
<tr>
<td>Ramos-Casals et al</td>
<td>164</td>
<td>Effective</td>
<td>Potentially progressive membranous LN, data pooled from 2 centers, Rituximab with cyclophosphamide</td>
</tr>
<tr>
<td>Pepper et al</td>
<td>18</td>
<td>Effective</td>
<td>Biopsy proven LN, pooled data from European cohort, rituximab in combination with cyclophosphamide or MMF</td>
</tr>
<tr>
<td>Central nervous system SLE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tokunaga et al</td>
<td>10</td>
<td>Effective</td>
<td>Rapid response in NP SLE</td>
</tr>
<tr>
<td>Narvaez et al</td>
<td>35</td>
<td>Effective</td>
<td>Clinical improvement; Steroid sparing effect</td>
</tr>
</tbody>
</table>

Abbreviations: SLE, systemic lupus erythematosus; MMF, mycophenolate mofetil; BILAG, British Isles Lupus Assessment Group; SLAM, Systemic Lupus Activity Measure; ANA, antinuclear antibodies; BLyS, B lymphocyte stimulator; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; LN, lupus nephritis; NP SLE, neuropsychiatric systemic lupus erythematosus.

background standard of care therapy confounds the effects of investigational agents.52,53

Summary

Caring for patients with systemic lupus erythematosus is a significant challenge. Rituximab seems to be a therapeutic option in cases of refractory diseases or recurrent flares despite the use of standard therapy. We cannot conclude that the promising results of open and multicenter-observational studies are more meaningful than results from double-blind placebo-controlled trials, but it would be unwise to reject the efficacy of an agent that targets a pathologic mechanism of the disease. We are in agreement that treatments should be more personalized and tailored case by case. For physicians who treat lupus patients, especially those patients with refractory disease who do not respond to standard treatment, data from open studies with rituximab can support the decision of the introduction of biologic therapy. As supported by off-label use experience, rituximab seems to be more effective in refractory diseases than in nascent lupus nephritis.
It may be necessary to conduct future research that defines the various biological mechanisms and genetic backgrounds that explain the varied manifestations of SLE and help predict response to treatment, allowing for more individualized or organ-specific therapies.

Disclosure
The authors report no conflict of interest in this work.

References


